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Leishmaniasis is a pestilent affliction that importunately needs better therapeutics neces-
sitated by the absence of effective vaccine, emergence as HIV co-infection, and the dread
of debilitating chemotherapy.The Leishmania parasites incapacitate host macrophages by
preventing the formation of phagolysosomes, impeding antigen presentation to T cells,
leading to suppression of cell-mediated immunity. An ideal approach to cure leishmaniasis
includes administration of antileishmanial compounds that can concomitantly establish an
effective Th1 response via restoration of requisite signaling between macrophages and
T cells, for subsequent activation of macrophages to eliminate intracellular amastigotes.
Plants have provided an opulent treasure of biomolecules that have fueled the discovery
of antileishmanial drugs. Modulation of immune functions using medicinal plants and their
products has emerged as an effective therapeutic strategy. Herein, we review the plant
extracts and natural products that have resulted in therapeutic polarization of host immu-
nity to cure leishmaniasis.These immunostimulatory phytochemicals as source of potential
antileishmanials may provide new strategies to combat leishmaniasis, alone or as adjunct
modality.
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INTRODUCTION
Leishmaniasis is a neglected; usually poverty-associated complex
vector-borne disease that is caused by more than 21 species
of parasites belonging to the order Kinetoplastida and family
Trypanosomatidae. The disease manifests into different clinical
indexes depending on the parasite tropism and ranges from self-
healing cutaneous lesions, to malign mucocutaneous leishmaniasis
and fatal visceral manifestations. The disease is endemic in 98
countries, where 10–12 million people are afflicted worldwide
with 1.5–2.5 million new cases, death toll of 70,000 and 350 mil-
lion at risk of developing the infection (1–3). Since Leishmania
parasites reside and multiply within the parasitophorous vacuoles
of macrophages, failure of host immunity to contain the infection
results in immunosuppression. Thus, the host becomes susceptible
to various secondary infections including HIV (4, 5).
The antiquated therapeutic modalities for leishmaniasis are
crippled because of variable efficacy, drug resistance, and pro-
nounced side effects. Even the known antileishmanial drugs such
as amphotericin B (AmB), sodium stibogluconate (SSG), and mil-
tefosine exert their antileishmanial effect via host immunomod-
ulation [(6) and references therein]. Modulation of the host
immune response via generation of antileishmanial vaccine would
certainly be a propitious step in leishmaniasis control, but is
impeded by the digenetic life cycle of Leishmania, and antigenic
diversity among different Leishmania species, making prospects
of a cross-protective vaccine a distant future (7, 8). Thus, in the
absence of any vaccine, a quintessential approach to control leish-
maniasis shall be based on discovery of drugs from alternative
sources that can directly kill the parasite as well as activate sentinels
of immune system for clearance of the pathogen. Herein, we fur-
ther elaborate the mechanisms employed by Leishmania parasites
to evade host immune responses, lacunae in current chemother-
apy and discuss potential role of natural immunomodulators in
antileishmanial therapy.
LEISHMANIA PARASITE-EVASION FROM HOST IMMUNE
DEFENSES
MODULATION OF NEUTROPHIL FUNCTIONS
Within 24 h of Leishmania infection, neutrophils are recruited to
the site of infection, serving as early and transitory host to Leish-
mania promastigotes (9). Although exact mechanisms underlying
the recruitment of neutrophils remain unclear, the role of both
parasites or vector-derived molecules is speculated (9, 10). The
role of neutrophils in Leishmania infection is variable, Leishmania
species specific, and also depends on the host genetics (11–14).
Although neutrophils are responsible for early containment of
different Leishmania species (15–18), they play equally pivotal
role in harboring the parasites till they reach their evolutionary
destined host cells, i.e., macrophages. Leishmania promastigotes
deviously modulate neutrophil phagocytic functions in more than
one way. Internalized Leishmania promastigotes block the pro-
duction of CXC-chemokine interferon gamma (IFN-γ) inducible
protein-10, which results in decreased recruitment and activa-
tion of natural killer (NK) cells and Th1 cells (10). Leishmania
donovani promastigotes have been shown to induce NETs (fibrous
traps of DNA, histones, and proteins) in which they get trapped
but escape their microbicidal activity by aid of lipophosphogyl-
can (LPG) (19). Leishmania parasites also extend the life span
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of neutrophils and delay their apoptosis by various mechanisms
(20, 21). Since ingestion of apoptotic neutrophils by macrophages
does not trigger macrophage microbicidal defenses, it creates safe
passage for stealth entry of Leishmania parasites. The theory that
neutrophils act as Trojan horses is well perceived in case of L. dono-
vani (10, 22), but there is also evidence that Leishmania parasites
escape neutrophils before infecting the macrophages (23), a Trojan
rabbit strategy where viable promastigotes hide in the shadow of
apoptotic neutrophils (9).
ENTRY INTO MACROPHAGES
In their quest for survival, Leishmania parasites face the ardu-
ous challenge to gain entry inside the macrophages and silence
their impeccable defenses. The parasites express a wide array
of ligands on their surfaces, which interact with a variety of
macrophage receptors. Some of the key receptors that mediate
promastigote–macrophage binding include the receptors for com-
plement, fibronectin, mannose–fucose, and other sugars [(24) and
references therein]. Interestingly, the foremost ligands employed
by parasite for its phagocytic uptake are not encoded by the para-
site itself; instead, parasite gets ingested into the macrophages via
opsonin-dependent pathways. The sharp-witted Leishmania par-
asites not only circumvent complement-mediated lysis but also
modulate the complement system for their active uptake inside
the macrophages. C3bi and C3b are two major complement sys-
tem components that bind to promastigote surface (25–28) and
facilitate their intracellular uptake via CR3 and CR1, respectively.
The uptake via CR3 is more advantageous since internalization
via these receptors does not result in oxidative burst and also
suppresses the secretion of IL-12 and other pro-inflammatory sig-
nals, thus hampering the initiation of cell-mediated immunity
(CMI) (29, 30).
ESTABLISHING INFECTION IN MACROPHAGES
Once inside the macrophage phagosomes, promastigotes create an
intracellular niche for their survival by silencing the macrophages
through multifarious schemes. Predominantly, Leishmania para-
sites retard phagosome maturation, delay enodosome–phagosome
fusion, inhibit hydrolytic enzymes in phagolysosomes, prevent
generation of reactive-nitrogen and -oxygen species, suppress
antigen presentation, and repress pro-inflammatory cytokine pro-
duction. LPG present on the surface of Leishmania parasites
retards phagosome maturation by inducing Cdc42- and Rac1 (Rho
family GTPases, F-actin regulators)-dependent F-actin accumula-
tion, which also involves inhibition of PKCα leading to impaired
recruitment of LAMP-1 and rab7 (31–34). It has been reported ear-
lier that incorporation of LPG selectively into one of the leaflets
of lipid bilayers of phagosome membrane alters its biophysical
properties making it less fusogenic [(31) and references therein].
LPG impairs the acquisition of vesicular proton-ATPase, which
is involved in acidification of phagolysosomes (35). Leishmania
parasites either decimate or suppress expression of major histo-
compatibility complex (36–38). Leishmania parasites also interfere
with protein expression of their host cells (39), suppress the secre-
tion of pro-inflammatory cytokines (IFN-γ, TNF-α, IL-6, IL-12),
and induce secretion of anti-inflammatory cytokines (IL-4, IL-
10, and TGF-β) via modulation of host cell signaling (40–42).
Thus, establishment of Leishmania infection involves complex
in-depth interactions between a vast repertoire of immunostimu-
lating and immunosuppressive molecules that finally determine a
species-dependent outcome of infection.
THERAPEUTIC MODALITIES
The pentavalent antimonials, SSG and Meglumine Antimoniate
(MA), have been employed in treatment of visceral leishmaniasis
(VL) and cutaneous leishmaniasis (CL) for more than 60 years.
The use of SSG and MA as first-line treatment for VL has been
already abandoned after failure rates of ~65% in endemic regions
of Bihar, India. Antimonials show variable efficacy against CL and
VL, and accompanying severe side effects have demerited their
use. The second line of drug AmB is now employed to treat the
antimony-resistant patients but the need of hospitalization, pro-
longed duration of treatment, and infusion-related side effects
are drawbacks. These constraints have now been overcome by
lipid formulations of AmB that prevent tissue retention, thereby
reducing the toxicity and promoting preferential uptake by retic-
uloendothelial cells that harbor the parasites. However, cost of
liposomal AmB is a serious limitation and frequent noxious effects
and drug resistance associated with pentamidine has also led to its
withdrawal. Paromomycin has been registered for use in India
against VL but is oto- and nephrotoxic. Miltefosine, the first oral
drug, is of limited use because of its teratogenicity (43–45).
NATURAL IMMUNOMODULATORS: ROLE IN
ANTILEISHMANIAL THERAPY
The drug discovery against leishmaniasis has been more reliant
on therapeutic switching rather than discovery of novel drugs.
Since elevation of host immunity is critical in parallel to the
drug-mediated killing of Leishmania parasites, the antileishma-
nial arsenal may be benefited by antileishmanials that can prong a
bifurcated attack, i.e., elimination of the parasites as well as restora-
tion of CMI. The potential of immunomodulators in treating
experimental leishmaniasis gained momentum with the discov-
ery of antileishmanial activity of imiquimod (46, 47), an agonist
for toll-like receptor 7, which is present on macrophages and den-
dritic cells (DC) and promotes the development of Th1 immune
response [(48) and references therein]. Several other synthetic
compounds such as S2 complex (an organic complex of copper
chloride, ascorbic acid, and nicotinamide) (49), acetyl salicylic
acid (50), and immunomodulatory peptide from cystatin (51)
have been demonstrated to possess dual immune-modulating and
antileishmanial activities.
Various herbal formulations and plant secondary metabolites
such as flavonoids, isoflavonoids, saponins, alkaloids, sesquiter-
penes, polysaccharides, tannins, indoles, and glucans are known
to be immunomodulatory in different diseases (52, 53). Among
natural resources, plants have been most extensively explored
for bioactive leishmanicidal and immunomodulatory compounds.
Plant extracts contain a plethora of biomolecules that can naturally
kill Leishmania parasites and also exert immunostimulatory prop-
erties, on otherwise depressed immune system during the diseased
state, as has been extensively reviewed in Table 1.
In brief, the studies examining immunomodulatory effect of
bioactive plant extracts or compounds have reported skewing of
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Table 1 | Immunomodulatory antileishmanial plant extracts or purified molecules thereof.
Plant extracts/purified
compounds/secondary
metabolites/herbal medicines
Leishmania
strain
Concentration (in vitro)/dose
regimen (in vivo)
Immunomodulatory
mechanism
Reference
Asparagus racemosus (whole
plant)
L. donovani (Dd8) b650 mg/kg b.w. +cisplatin
(5 mg/kg b.w.) for 5 days i.p.
↑ INF-γ, IL-2, IgG2a Sachdeva et al.
(54)↓ IL-4, IL-10, IgG1
Induced DTH response
Allium sativum in combination
withTridax procumbens
Leishmania major
[Hd-18-(MHET/MX/
97/Hd-18)]
b40 mg/kg b.w. (1:1) i.p. daily for
2 weeks
↑ IgG2a/IgG1 ratio Gamboa-Leon
et al. (55)
Galactomannan (isolated from
seeds of Mimosa scabrella)
Leishmania
amazonensis (MHOM/
BR173/M2269)
250µg/ml ↑ IL-1β, IL-6 and NO production Adriazola et al.
(56)TNF-α and IL-10 levels unaffected
aLicarin A (neolignan, plant
secondary metabolite)
L. major
(MHOM/IL/1980/FN)
5 and 20µg/ml ↓ IL-6 and IL-10 Néris et al. (57)
No significant alterations in TNF-α and
NO levels
Niranthrin (lignan isolated from
aerial parts of Phyllanthus
amarus)
L. donovani
(MHOM/IN/1983/
AG83)
b5 and 10 mg/kg b.w. twice for
3 weeks
↑ NO, ROS, iNOS Chowdhury
et al. (58)Induced lymphoproliferation
↑ IFN-γ, TNF-α, and IL-12p70
↑ IgG2a levels
↓ IL-10 and TGF-β
No change in IL-4 expression and IgG1
aBerberine chloride (quaternary
isoquinoline alkaloid)
L. donovani isolate
(NS2)
2.5 and 10µM ↑ NO production Saha et al. (59)
Activated iNOS
↑ mRNA expression of IL-12p40
↓ IL-10
Upregulated p38 MAPK pathway
Picroliv (iridoid glycoside mixture
from Picrorhiza kurroa) in
combination with fluconazole
and miltefosine
L. donovani
(MHOM/IN/80/Dd8)
Picroliv (10 mg/kg)+Fluconazole
(50 mg/kg)+Miltefosine
(5 mg/kg b.w.) in hamsters
Induced lymphoproliferation Shakya et al.
(60)↑ ROS, hydrogen peroxide, RNS
↑ Phagocytic activity
Spiranthera odoratissima (fruit
hexane extract and its alkaloid
Skimmianine)
Leishmania
braziliensis
1.6µg/ml ↑ NO production Dos Santos
et al. (61)↓ IL-10 production
Echium amoenum
(flowers-aqueous and alcoholic
extracts)
L. major
(MRHO/IR/75/ER)
b250, 750, and 3750 mg/kg b.w. ↑ IFN-γ Hosseini and
Abolhassani
(62)
Induced lymphoproliferation
IL-4 levels unaffected
A. sativum (aqueous extract) L. major
(MRHO/IR/75/ER)
37 mg/ml ↑ INF-γ and iNOS mRNA expression
levels
Gharavi et al.
(63)
A.sativum (aqueous extract) L. major
(MRHO/IR/75/ER)
37 mg/ml ↑ IL-12 Gharavi et al.
(64)↓ IL-10
aArtemisinin (sesquiterpene
lactone from Artemisia annua)
L. donovani 10 and 25µM ↑ NO production Sen et al. (65)
b10 and 25 mg/kg b.w. ↑ IL-12 and IFN-γ
Kalanchoe pinnata
(leaves-aqueous extract)
Leishmania chagasi b400 mg/kg b.w. by intragastric
gavage from day 1–29 of
infection
Depressed serum IgG levels Gomes et al.
(66)↓ IL-4, INF-γ
↑ NO production
(Continued)
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Table 1 | Continued
Plant extracts/purified
compounds/secondary
metabolites/herbal medicines
Leishmania
strain
Concentration (in vitro)/dose
regimen (in vivo)
Immunomodulatory
mechanism
Reference
Warburgia ugandensis, Psiadia
punctulata, and Chasmanthera
dependens (bark-aqueous
extract)
L. major
(IDU/KE/83=NLB-
144)
1000µg/ml ↑ NO production Githinji et al.
(67)
Himatanthus sucuuba latex L. amazonensis
(WHOM/BR/75/Josefa
strain)
200µg/ml ↑TNF-α and NO production Soares et al.
(68)↓TGF-β
A.sativum (methanolic extract) L. donovani (NLB065) 250µg/ml ↑ NO production Wabwoba
et al. (69)
Xylopia discreta (leaf methanolic
extract and essential oil)
L. panamensis
(MHOM/CO/87/UA140)
Different concentrations ↑ Monocyte chemoattractant protein-1
(MCP-1) expression
López et al.
(70)
aQuassin (one of the quassinoids
isolated from Quassia amara)
L. donovani
(MHOM/IN/1983/AG83)
25µg/ml ↑ iNOS2 expression Bhattacharjee
et al. (71)↑TNF-α, and IL-12p70
↓TGF-β and IL-10
A.sativum (aqueous extract) Leishmania mexicana
(MNYC/BZ/62/M379)
37µg/ml ↑ NO production Gamboa-León
et al. (72)b20 and 60 mg/kg b.w. for
2 weeks i.p.
↑ IFN-γ
Pelargonium sidoides
(aqueous-ethanolic formulation
of roots and methanol insoluble
fraction of this extract)
L. major 50µg/ml ↑ iNOS activity
↑ IFN-γ, IL-12, IL-18 mRNA levels
Trun et al. (73)
aPlant polyphenols (Tannins and
structurally related compounds)
L. major and
L. donovani
promastigotes
Different concentrations Moderate effect on NO production
↑TNF and INF like activities
Kolodziej and
Kiderlen (74)
Desmodium gangeticum
(Aminoglucosyl glycerolipid and
Cerebroside)
L. donovani 100µg/ml ↑ NO production Mishra et al.
(75)
Canova medication (Aconitum
napellus, Arsenium album,
Bryonia alba, andThuya
occidentalis)
L. amazonensis
(MHOM/BR/73/M2269)
20 and 40% ↑ NO production Pereira et al.
(76)
Croton cajucara (Essential oil) L. amazonensis
(Raimundo strain,
MHOM/BR/76/Ma-5)
1, 1.5, and 0.2 ng/ml ↑ NO production do Socorro
et al. (77)
A.sativum extract L. major
(MRHO/IR/76/ER)
bGarlic (20 mg/kg b.w.)
+glucantime (60 mg/kg b.w.)
daily for 2 weeks
↑ IFN-γ and IL-2
↓IL-4 and IL-10
Ghazanfari
et al. (78)
aSynthetic molecules of plant origin.
bStudies carried out in BALB/c mice.
immune response from Th2 (diseased state) to Th1 (cure) by
causing the up- or downregulation of pro-inflammatory (acti-
vating Th1) and anti-inflammatory (promoting Th2) cytokines,
respectively. The most commonly assessed immunomodulatory
parameter for parasite clearance is stimulation of nitric oxide
(NO). NO is the principle effector molecule in killing of Leishma-
nia amastigotes (79) and is either estimated directly as nitrite con-
centration in culture supernatant or indirectly by the changes in
nitric oxide synthase (iNOS) gene expression levels. NO-mediated
killing of Leishmania parasites by tannins and related compounds
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has also been demonstrated (74). IL-12 is the central cytokine
produced by DC, NK, and T cells, which activates macrophages to
produce IFN-γ and TNF-α. Different plant secondary metabolites
and extracts have induced IL-12 up-regulation (Table 1), indicat-
ing the worthy potential of natural resources. Macrophages also
produce IL-18, which in synergism with IL-12 stimulates IFN-
γ production and aids in parasite clearance (80, 81). Pelargonium
sidoides extracts have been shown to increase mRNA levels of IL-18
in Leishmania major infection (73).
In parallel to stimulation of IL-12 and other pro-inflammatory
cytokines, expression levels of IL-4, IL-10, and TGF-β have also
been widely investigated (Table 1). IL-4, IL-10, and TGF-β inhibit
the production of IFN-γ from macrophages. IL-4 is known to
potently inhibit macrophage activation, but IL-10 plays a car-
dinal role in progression of both CL and VL. In both, murine
and human VL, despite the production of adequate amounts of
IFN-γ, the hosts are unable to mount an effective CMI response,
and this host inefficiency is attributed to increased levels of IL-
10. Kane and Mosser (82) demonstrated that host-derived IgG
present on Leishmania amastigotes ligates to Fcγ receptors on
inflammatory macrophages and modulates them to secrete IL-10
in high amounts in CL. The levels of these Th2 cytokines have been
observed to decline along with successful recuperation of CMI
after treatment with immunomodulatory extracts and molecules
of natural origin (Table 1).
It can thus be well established that natural immunomodulators
can skew the Th1–Th2 balance but pro- and anti-inflammatory
cytokines play diverse and inter-regulatory roles. As also supported
by Couper et al. (83), understanding the dynamics of Th1–Th2
paradigm has changed over the years and it is conceived that both
Th1 and Th2 cells can mediate inflammation as well as aid para-
site clearance. For instance, Néris et al. (57) reported that Licarin
A, treated L. major-infected macrophages exhibit decline in IL-6
as well as IL-10 levels. IL-6 is a characteristic pro-inflammatory
cytokine, which also negatively regulates Th1 differentiation and
promotes CD4+ Th2 differentiation mediated by IL-4 (84). How-
ever, as the study presented only the in vitro data, and also the pro-
or anti-immunopotentiating effect can be dose dependent (85)
further in vivo studies may throw proper light on mechanism of
action of Licarin A.
CONCLUSION
The use of herbal preparations to modulate the immune response
to cure or avert diseases has been described in traditional sys-
tems of Indian, Unani, and Chinese medicine. The natural sub-
stances with dual, antileishmanial, and immunomodulatory prop-
erties have been carefully evaluated, however, it should be noted
that human leishmaniasis varies in immunological pattern from
murine leishmaniasis. Thus, the natural immunomodulators need
to be evaluated more systematically and specifically in terms
of dosage, biodistribution, kinetics, and interactions with other
drugs and their putative role in other co-infections should also be
examined.
Nonetheless, the concept of using natural immunomodulators
to treat parasitic infections including leishmaniasis holds mighty
potential in achieving the control of this disease. These natural
immunomodulatory molecules can serve as scaffolds for synthesis
and discovery of new immunodrugs. Also, the use of natural
immunomodulators in synergy with existing drugs may involve
the functional manipulation of multiple molecular targets leading
to improved therapeutic efficacy and reduced toxicity.
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